Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
Summary
The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high dose challenge, resulting in strongly reduced viral infection and replication in upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.
Competing Interest Statement
N.P.K. is a co-founder, shareholder, and chair of the scientific advisory board of Icosavax, Inc. All other authors declare no competing interests.
Subject Area
- Biochemistry (11744)
- Bioengineering (8751)
- Bioinformatics (29193)
- Biophysics (14968)
- Cancer Biology (12094)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14178)
- Epidemiology (2067)
- Evolutionary Biology (18303)
- Genetics (12244)
- Genomics (16801)
- Immunology (11866)
- Microbiology (28082)
- Molecular Biology (11592)
- Neuroscience (60959)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4957)
- Plant Biology (10427)
- Synthetic Biology (2885)
- Systems Biology (7339)
- Zoology (1651)